publication date: May. 24, 2019
UPenn study shows adding bevacizumab improves OS in NSCLC
New research from the Abramson Cancer Center at the University of Pennsylvania, published in the May 2019 issue of the Journal of the National Comprehensive Cancer Network uses a large, real-world dataset to demonstrate there is a modest but consistent survival benefit associated with adding bevacizumab to carboplatin-pemetrexed when treating advanced non-squamous non-small cell lung cancer.
This combination is already a common clinical practice, but there has never been a randomized prospective clinical trial to determine whether adding bevacizumab confers any survival benefit.
“Our results suggest that in patients with a contraindication to immunotherapy, such as connective tissue, rheumatologic, or interstitial lung disease, bevacizumab may be a reasonable alternative, instead of pembrolizumab, to add to carboplatin-pemetrexed,” lead author Stephen J. Bagley, assistant professor of Hematology-Oncology, Abramson Cancer Center, said in a statement.
“Many oncologists were already using carboplatin-pemetrexed-bevacizumab for patients with advanced non-squamous NSCLC, but this study suggests there is indeed an improvement in overall survival when bevacizumab is added. What’s more, I was surprised to learn that the survival benefit of bevacizumab persisted even in older patients and after adjusting for brain metastases, hemoptysis, and anticoagulation use.”
The retrospective study used nationally representative electronic health record data from Flatiron Health and supplemented these data with the researchers’ institutional experience to account for confounding clinical variables not captured in the Flatiron database.
These data cover a total of 4,724 lung cancer patients treated between January 1, 2011 and June 30, 2017 across more than 260 community cancer clinics. 2,759 patients (58%) received carboplatin/pemetrexed while 1,965 (42%) received carboplatin/pemetrexed/bevacizumab.
The … Continue reading UPenn study shows adding bevacizumab improves OS in NSCLC
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.